novartis_window

Novartis CEO sets aside $700 million to settle bribery lawsuit

pharmafile | July 18, 2019 | News story | Business Services, Sales and Marketing |  Novartis, bribery, lawsuit, pharma, sales 

Vas Narasimhan, Novartis’ CEO, has set aside $700 million to settle a bribery lawsuit in the United States.

Speaking in a conference call, Narasimhan said he sought to bring an end to the whistle-blower lawsuit in which Novartis was accused of bribing doctors to boost subscriptions of its drugs.

“Consistent with our efforts to resolve our legacy compliance-related allegations, right now we’re working in settlement discussions to resolve the civil suit…on speaker programs and other promotional events that happened between 2002 and 2011”

Advertisement

“We’ve provisioned approximately $700 million for any potential settlement,” Narashimhan said.

The statements come as the Swiss multinational lifted full-year sales and profit targets. Novartis saw second-quarter core operating income increase by 20% to $3.6 billion while sales were up 8% to $11.8 billion compared to the $11.54 billion forecast by analysts.

The increases are being driven by innovative medicines sales and increased demand for generics from Novartis’ Sandoz unit.  

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA

As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

The Gateway to Local Adoption Series

Latest content